Ipatasertib
Ipatasertib[edit | edit source]
Ipatasertib is an investigational small molecule inhibitor of the protein kinase B (AKT) pathway, which is being studied for its potential use in the treatment of various types of cancer. It is a targeted therapy designed to interfere with the signaling pathways that promote cancer cell growth and survival.
Mechanism of Action[edit | edit source]
Ipatasertib works by inhibiting the activity of the AKT enzyme, which is a key component of the PI3K/AKT/mTOR pathway. This pathway is often dysregulated in cancer, leading to increased cell proliferation and survival. By blocking AKT, ipatasertib aims to reduce tumor growth and enhance the effectiveness of other anticancer therapies.
Clinical Development[edit | edit source]
Ipatasertib is currently undergoing clinical trials to evaluate its safety and efficacy in combination with other treatments. It is being tested in various cancers, including breast cancer, prostate cancer, and gastric cancer.
Breast Cancer[edit | edit source]
In breast cancer, ipatasertib is being studied in combination with paclitaxel and other chemotherapeutic agents. The focus is on patients with triple-negative breast cancer, a subtype that lacks estrogen receptor, progesterone receptor, and HER2/neu expression.
Prostate Cancer[edit | edit source]
For prostate cancer, ipatasertib is being evaluated in combination with abiraterone and prednisone. The trials are targeting patients with metastatic castration-resistant prostate cancer (mCRPC), a form of the disease that no longer responds to hormonal therapy.
Gastric Cancer[edit | edit source]
In gastric cancer, ipatasertib is being tested alongside standard chemotherapy regimens. Researchers are investigating its potential to improve outcomes in patients with advanced or metastatic disease.
Side Effects[edit | edit source]
The side effects of ipatasertib are similar to those of other targeted therapies and may include diarrhea, rash, nausea, and fatigue. As with any investigational drug, the safety profile is continuously monitored during clinical trials.
Future Directions[edit | edit source]
Ongoing research aims to better understand the role of ipatasertib in cancer treatment and to identify biomarkers that predict response to therapy. The ultimate goal is to integrate ipatasertib into personalized treatment regimens that maximize efficacy while minimizing adverse effects.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
